Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01612936 · ClinicalTrials.gov registry record · Phase 1
T Cell Effector and Regulatory Mechanisms in Asthma
A Phase 1 study of Asthma and Allergies, sponsored by Andrew D. Luster, M.D.,Ph.D..
- Completed
- Registry status
- Phase 1
- Development phase
- 168
- Enrollment target
- 1
- Study location
NCT01612936 is a Phase 1 study of Asthma and Allergies that has completed, run by Andrew D. Luster, M.D.,Ph.D.. The registered enrollment target is 168 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01612936, a Phase 1 study of Asthma and Allergies, has completed, sponsored by Andrew D. Luster, M.D.,Ph.D..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 168 participants
- Enrollment target
- 1
- Study location
Study Summary
The specific hypothesis for this study is that there are fundamental differences in T effector and T regulatory cell responses in the lung to allergens in allergic asthma (AA) when compared to allergic nonasthmatics (ANA) that account for the difference in clinical responses. We will address this by comparing T cell responses in AA versus ANA subjects. These experiments will correlate T cell responses with measures of airway physiology using state-of-the art lung imaging and examine mechanisms controlling T cell activation in the airways of AA and the function of airway T regulatory cells during AA.
Interventions
- BIOLOGICAL Bronchoscopy, Segmental Allergen Challenge and Broncheoalveolar Lavage
- PROCEDURE PET-CT imaging(13NN perfusion/ventilation, 18FDG inflammation, and CT imaging)
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2012-09 |
| Est. Completion | 2016-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01612936
The ClinicalTrials.gov registry entry for NCT01612936 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 168 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (89% lower). The listed sponsor is Andrew D. Luster, M.D.,Ph.D., which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Bronchoscopy, Segmental Allergen Challenge and Broncheoalveolar Lavage is the first listed.
NCT01612936 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01612936 about?
NCT01612936 is a clinical study titled "T Cell Effector and Regulatory Mechanisms in Asthma". The specific hypothesis for this study is that there are fundamental differences in T effector and T regulatory cell responses in the lung to allergens in allergic asthma (AA) when compared to allergic nonasthmatics (ANA) that account for the difference in clinical responses. We will address this by...
What is the current status of trial NCT01612936?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 168 participants. The study started on 2012-09. Estimated completion is 2016-09.
What conditions does trial NCT01612936 study?
This clinical trial studies the following conditions: Asthma, Allergies.
What interventions are being tested in trial NCT01612936?
The interventions under investigation include: Bronchoscopy, Segmental Allergen Challenge and Broncheoalveolar Lavage (BIOLOGICAL), PET-CT imaging(13NN perfusion/ventilation, 18FDG inflammation, and CT imaging) (PROCEDURE).
Who is sponsoring clinical trial NCT01612936?
This trial is sponsored by Andrew D. Luster, M.D.,Ph.D., which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01612936 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease
RECRUITING · Phase 1
-
A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma
RECRUITING · Phase 1
-
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
RECRUITING · Phase 1
-
A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.